Hennion & Walsh Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-50,374
| Closed | -$2.03M | – | 957 |
|
|
2026
Q1 | $2.03M | Sell |
50,374
-1,559
| -3% | -$33.6K | 0.07% | 351 |
|
|
2025
Q4 | $1.3M | Buy |
51,933
+3,804
| +8% | +$89.2K | 0.05% | 457 |
|
|
2025
Q3 | $1.09M | Sell |
48,129
-885
| -2% | -$20.6K | 0.04% | 490 |
|
|
2025
Q2 | $848K | Buy |
49,014
+4,848
| +11% | +$89.7K | 0.03% | 529 |
|
|
2025
Q1 | $966K | Buy |
44,166
+14,426
| +49% | +$399K | 0.04% | 480 |
|
|
2024
Q4 | $949K | Buy |
29,740
+17,115
| +136% | +$515K | 0.04% | 475 |
|
|
2024
Q3 | $364K | Sell |
12,625
-1,325
| -9% | -$49.1K | 0.02% | 699 |
|
|
2024
Q2 | $535K | Sell |
13,950
-118
| -0.8% | -$5.34K | 0.03% | 574 |
|
|
2024
Q1 | $827K | Buy |
14,068
+1,766
| +14% | +$113K | 0.04% | 470 |
|
|
2023
Q4 | $736K | Sell |
12,302
-172
| -1% | -$8.72K | 0.04% | 479 |
|
|
2023
Q3 | $475K | Buy |
12,474
+899
| +8% | +$39.5K | 0.03% | 535 |
|
|
2023
Q2 | $1.05M | Buy |
11,575
+229
| +2% | +$19.8K | 0.06% | 367 |
|
|
2023
Q1 | $748K | Buy |
11,346
+1,928
| +20% | +$111K | 0.05% | 417 |
|
|
2022
Q4 | $487K | Sell |
9,418
-48,299
| -84% | -$2.56M | 0.03% | 509 |
|
|
2022
Q3 | $3.94M | Sell |
57,717
-3,260
| -5% | -$193K | 0.26% | 97 |
|
|
2022
Q2 | $2.76M | Sell |
60,977
-58,345
| -49% | -$2.66M | 0.17% | 156 |
|
|
2022
Q1 | $6.06M | Sell |
119,322
-17,438
| -13% | -$770K | 0.32% | 75 |
|
|
2021
Q4 | $6.47M | Sell |
136,760
-45,445
| -25% | -$1.79M | 0.32% | 84 |
|
|
2021
Q3 | $6M | Sell |
182,205
-6,451
| -3% | -$362K | 0.32% | 77 |
|
|
2021
Q2 | $11.9M | Buy |
188,656
+14,600
| +8% | +$753K | 0.64% | 27 |
|
|
2021
Q1 | $7.47M | Buy |
+174,056
| New | +$8.24M | 0.45% | 42 |
|
Other funds holding APLS
Hennion & Walsh Asset Management's APLS Position: Q2 2026 in Review
Hennion & Walsh Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 50,374 shares — an estimated $2.03M sold.
Hennion & Walsh Asset Management first reported a position in APLS in Q1 2021 and held it in 21 quarters. The position peaked at $11.9M in Q2 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Hennion & Walsh Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Hennion & Walsh Asset Management sold 50,374 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.03M.
- Hennion & Walsh Asset Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 21 quarters.
- Hennion & Walsh Asset Management's Apellis Pharmaceuticals position peaked at $11.9M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.